Literature DB >> 30110578

National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment.

Peter B Bach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30110578     DOI： 10.1056/NEJMp1807382

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Mechanisms of resistance to CAR T cell therapy.

Authors:  Nirali N Shah; Terry J Fry
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

2.  The First Year of HemaSphere and Many More to Come.

Authors:  Andreas Engert; Jan Cools
Journal:  Hemasphere       Date:  2018-11-29

3.  ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Anne Rain T Brown; Irfan Jindani; Judd Melancon; Rose Erfe; Jason Westin; Lei Feng; Cristina Gutierrez
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

Review 4.  Disparities in Survival and Health Outcomes in Childhood Leukemia.

Authors:  Lena E Winestone; Richard Aplenc
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 5.  Value and affordability of CAR T-cell therapy in the United States.

Authors:  Salvatore Fiorenza; David S Ritchie; Scott D Ramsey; Cameron J Turtle; Joshua A Roth
Journal:  Bone Marrow Transplant       Date:  2020-05-30       Impact factor: 5.483

Review 6.  Role of bridging therapy during chimeric antigen receptor T cell therapy.

Authors:  Shakthi T Bhaskar; Bhagirathbhai R Dholaria; Salyka M Sengsayadeth; Bipin N Savani; Olalekan O Oluwole
Journal:  EJHaem       Date:  2021-11-19

Review 7.  Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.

Authors:  Stacie Ittershagen; Solveig Ericson; Lamis Eldjerou; Ali Shojaee; Eric Bleickardt; Manisha Patel; Tetiana Taran; Oezlem Anak; Charlene Hall; Mimi Leung; Deborah Roccoberton; Florence Salmon; Miriam Fuchs; Vadim Romanov; David Lebwohl
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

Review 8.  Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.

Authors:  Valentin Barsan; Sneha Ramakrishna; Kara L Davis
Journal:  Curr Oncol Rep       Date:  2020-01-29       Impact factor: 5.075

Review 9.  Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.

Authors:  Hashim Mann; Raymond L Comenzo
Journal:  Onco Targets Ther       Date:  2022-07-22       Impact factor: 4.345

Review 10.  The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.

Authors:  Yasmin R Mohseni; Sim L Tung; Caroline Dudreuilh; Robert I Lechler; Gilbert O Fruhwirth; Giovanna Lombardi
Journal:  Front Immunol       Date:  2020-07-24       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.